On November 9, 2026, the U.S. Food and Drug Administration announced it is requiring a new vision warning on every GLP-1 diabetes and weight-loss drug, including Ozempic, Wegovy and Mounjaro. The FDA is ordering drugmakers to add information about non-arteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition that can cause sudden vision loss, to the Warnings and Precautions section of their labels, according to the FDA’s Drug Safety Communication.
For people who lost vision after taking one of these drugs, the warning is an important development, and it comes as lawsuits over GLP-1 vision loss move forward in federal court here in Philadelphia.
The FDA’s requirement applies to the entire class of GLP-1 receptor agonists, including:
NAION happens when blood flow to the optic nerve is reduced, damaging the nerve. It typically causes sudden, painless vision loss in one eye, which the FDA notes patients may first notice when they wake up. The World Health Organization describes NAION as a leading cause of vision loss in adults and says the vision loss is generally irreversible, with no effective treatment currently available, according to a 2025 WHO alert.
The FDA concluded there is a “potential increased risk” of NAION with GLP-1 drugs. Among the evidence it reviewed was an analysis of 126 clinical trials, in which NAION occurred at a rate of 6.4 cases per 100,000 person-years among patients taking a GLP-1 drug, compared with 3.8 among patients taking a placebo.
The agency noted limits in the evidence. NAION is rare, many of its risk factors, such as diabetes, high blood pressure and sleep apnea, are common among people who take these drugs, and the FDA did not identify a biological mechanism in animal studies. Even so, it decided the potential risk was serious enough to require a warning across the entire drug class.
In June 2025, the European Medicines Agency’s safety committee concluded that NAION is a very rare side effect of the semaglutide drugs Ozempic, Rybelsus and Wegovy, meaning it may affect up to 1 in 10,000 people taking them, the EMA reported. European regulators advised that semaglutide treatment should be stopped if NAION is confirmed.
People who developed NAION after taking GLP-1 drugs have filed lawsuits against Novo Nordisk, the maker of Ozempic, Wegovy and Saxenda, and Eli Lilly, the maker of Trulicity, Mounjaro and Zepbound. In December 2025, federal vision loss cases were combined into a multidistrict litigation, MDL No. 3163, before Judge Karen S. Marston in the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia, according to the court. It is the second MDL in that court involving GLP-1 drugs; a separate MDL covers gastrointestinal injuries.
The lawsuits allege that the drugmakers failed to adequately warn patients and doctors about the risk of vision loss. Because these are failure-to-warn claims, what the drug labels said, and when, is central to the cases. The FDA’s decision to require a NAION warning is a significant development, though it does not by itself decide whether the companies are liable. The litigation is ongoing, and no outcome is guaranteed.
You may have a claim if you or a loved one:
Legal deadlines apply, and the time to file can depend on when you were diagnosed and when you learned your vision loss may be linked to the drug. Do not wait to get advice.
Wieand Parker Arreola, PLLC, is based in Center City Philadelphia, close to the federal courthouse where MDL 3163 is being litigated. We represent people in Pennsylvania and New Jersey who were harmed by dangerous drugs. Call (215) 666-7777 or contact us online for a free consultation. Learn more on our Ozempic vision loss lawsuit page and our defective drug page.
This article provides general information and is not legal or medical advice. Do not stop or change any medication without talking to your doctor. Reading this article does not create an attorney-client relationship. Prior results do not guarantee a similar outcome.